

HYDROGEL COMPOSITIONS COMPRISING GASDERMIN D AND AN ESCRT INHIBITOR AND METHODS OF USE THEREOF

View U.S. Patent Application Publication No. US-2024-0042054 in PDF format.

WARF: P220290US02

Inventors: Quanyin Hu, Zhaoting Li

The Invention

UW-Madison researchers have developed a novel approach for enhancing pyroptosis, which could prove beneficial in treating cancer. The inventors combine intracellular delivery of gasdermin with a small molecule that interferes with membrane repair in a single hydrogel nanoparticle. The gasdermin is delivered using a bacterial based vector (VNP-GD) and a calcium chelator (EI) is adhered to a nanoparticle (EI-NP). Calcium chelation blocks influx-triggered ESCRT III-dependent membrane repair. A biodegradable hydrogel matrix is used as a carrier to deliver and sustainably release the VNP-GD and EI-NP.

Key Benefits

- · Platform delivery method
- · Compatible with a range of therapeutic modalities
- Sustainable release

Tech Fields

- Drug Delivery : Small molecules
- Therapeutics & Vaccines : Oncology

For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or 608-960-9847

We use cookies on this site to enhance your experience and improve our marketing efforts. By continuing to browse without changing your browser settings to block or delete cookies, you agree to the storing of cookies and related technologies on your device. See our privacy policy

